Concepedia

Kami J. Maddocks

KJ

Statistics

Publications

118

Citations

8.9K

H-Index

45

Active since

2003

Affiliations

The Ohio State University(Current)

The University of Texas MD Anderson Cancer Center

The Ohio State University Wexner Medical Center

Cornell University

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Kami J. Maddocks is an author at The Ohio State University specializing in oncology, medicine, and immunotherapy.

Publications per year

2003–2024

118

Publications

118

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan et al. · Blood · 2013 · 796 citations

Life Sciences, Immunology, Pharmacology +14

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

Kami J. Maddocks, Amy S. Ruppert, Gerard Lozanski et al. · JAMA Oncology · 2015 · 576 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

Gilles Salles, Johannes Duell, Eva González‐Barca et al. · The Lancet Oncology · 2020 · 519 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

<i>BTK</i><sup>C481S</sup>-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

Jennifer A. Woyach, Amy S. Ruppert, Daphne Guinn et al. · Journal of Clinical Oncology · 2017 · 471 citations

Medicine, Hematology, Oncology +16

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Joseph A. Fraietta, Kyle A. Beckwith, Prachi Patel et al. · Blood · 2016 · 461 citations · Full text

Life Sciences, Immunology, Oncology +12

1–5 of 118